UpHealth, Inc.
UpHealth, Inc. UPH Peers
See (UPH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UPH | $0.30 | +9.13% | 5.33M | -0.07 | -$4.50 | N/A |
| VEEV | $232.99 | -1.08% | 37.97B | 53.93 | $4.32 | N/A |
| GEHC | $69.16 | -0.40% | 31.67B | 14.53 | $4.76 | +0.19% |
| GEHCV | $56.00 | -4.08% | 25.46B | N/A | N/A | +0.19% |
| DOCS | $51.05 | -0.42% | 9.60B | 45.99 | $1.11 | N/A |
| SGFY | $30.49 | +0.07% | 8.93B | 70.91 | $0.43 | N/A |
| HQY | $99.01 | -1.07% | 8.58B | 90.83 | $1.09 | N/A |
| RCM | $14.31 | N/A | 6.04B | -102.21 | -$0.14 | N/A |
| BTSGU | $81.50 | -1.88% | 4.19B | N/A | N/A | N/A |
| BTSG | $23.23 | +1.35% | 4.05B | 86.04 | $0.27 | N/A |
Stock Comparison
UPH vs VEEV Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, VEEV has a market cap of 37.97B. Regarding current trading prices, UPH is priced at $0.30, while VEEV trades at $232.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas VEEV's P/E ratio is 53.93. In terms of profitability, UPH's ROE is -1.05%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, UPH is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs GEHC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, GEHC has a market cap of 31.67B. Regarding current trading prices, UPH is priced at $0.30, while GEHC trades at $69.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas GEHC's P/E ratio is 14.53. In terms of profitability, UPH's ROE is -1.05%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, UPH is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs GEHCV Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, GEHCV has a market cap of 25.46B. Regarding current trading prices, UPH is priced at $0.30, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas GEHCV's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, UPH is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs DOCS Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, DOCS has a market cap of 9.60B. Regarding current trading prices, UPH is priced at $0.30, while DOCS trades at $51.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas DOCS's P/E ratio is 45.99. In terms of profitability, UPH's ROE is -1.05%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, UPH is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SGFY Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SGFY has a market cap of 8.93B. Regarding current trading prices, UPH is priced at $0.30, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SGFY's P/E ratio is 70.91. In terms of profitability, UPH's ROE is -1.05%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, UPH is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs HQY Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, HQY has a market cap of 8.58B. Regarding current trading prices, UPH is priced at $0.30, while HQY trades at $99.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas HQY's P/E ratio is 90.83. In terms of profitability, UPH's ROE is -1.05%, compared to HQY's ROE of +0.05%. Regarding short-term risk, UPH is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs RCM Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, RCM has a market cap of 6.04B. Regarding current trading prices, UPH is priced at $0.30, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas RCM's P/E ratio is -102.21. In terms of profitability, UPH's ROE is -1.05%, compared to RCM's ROE of -0.02%. Regarding short-term risk, UPH is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs BTSGU Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, BTSGU has a market cap of 4.19B. Regarding current trading prices, UPH is priced at $0.30, while BTSGU trades at $81.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas BTSGU's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, UPH is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs BTSG Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, BTSG has a market cap of 4.05B. Regarding current trading prices, UPH is priced at $0.30, while BTSG trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas BTSG's P/E ratio is 86.04. In terms of profitability, UPH's ROE is -1.05%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, UPH is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs ONEM Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ONEM has a market cap of 3.40B. Regarding current trading prices, UPH is priced at $0.30, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ONEM's P/E ratio is -7.77. In terms of profitability, UPH's ROE is -1.05%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, UPH is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs PRVA Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, PRVA has a market cap of 2.79B. Regarding current trading prices, UPH is priced at $0.30, while PRVA trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas PRVA's P/E ratio is 190.50. In terms of profitability, UPH's ROE is -1.05%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, UPH is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs WGS Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, WGS has a market cap of 2.04B. Regarding current trading prices, UPH is priced at $0.30, while WGS trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas WGS's P/E ratio is -51.51. In terms of profitability, UPH's ROE is -1.05%, compared to WGS's ROE of -0.17%. Regarding short-term risk, UPH is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs PINC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, PINC has a market cap of 1.90B. Regarding current trading prices, UPH is priced at $0.30, while PINC trades at $23.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas PINC's P/E ratio is 22.61. In terms of profitability, UPH's ROE is -1.05%, compared to PINC's ROE of +0.03%. Regarding short-term risk, UPH is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CERT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CERT has a market cap of 1.85B. Regarding current trading prices, UPH is priced at $0.30, while CERT trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CERT's P/E ratio is -571.00. In terms of profitability, UPH's ROE is -1.05%, compared to CERT's ROE of -0.00%. Regarding short-term risk, UPH is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs PGNY Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, PGNY has a market cap of 1.76B. Regarding current trading prices, UPH is priced at $0.30, while PGNY trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas PGNY's P/E ratio is 36.00. In terms of profitability, UPH's ROE is -1.05%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, UPH is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs NXGN Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, NXGN has a market cap of 1.61B. Regarding current trading prices, UPH is priced at $0.30, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas NXGN's P/E ratio is -266.00. In terms of profitability, UPH's ROE is -1.05%, compared to NXGN's ROE of +0.03%. Regarding short-term risk, UPH is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SDGR Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SDGR has a market cap of 1.57B. Regarding current trading prices, UPH is priced at $0.30, while SDGR trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SDGR's P/E ratio is -8.14. In terms of profitability, UPH's ROE is -1.05%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, UPH is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs PHR Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, PHR has a market cap of 1.43B. Regarding current trading prices, UPH is priced at $0.30, while PHR trades at $24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas PHR's P/E ratio is -23.59. In terms of profitability, UPH's ROE is -1.05%, compared to PHR's ROE of -0.23%. Regarding short-term risk, UPH is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs AGTI Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, AGTI has a market cap of 1.37B. Regarding current trading prices, UPH is priced at $0.30, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas AGTI's P/E ratio is -71.79. In terms of profitability, UPH's ROE is -1.05%, compared to AGTI's ROE of -0.03%. Regarding short-term risk, UPH is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs GDRX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, GDRX has a market cap of 1.34B. Regarding current trading prices, UPH is priced at $0.30, while GDRX trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas GDRX's P/E ratio is 53.43. In terms of profitability, UPH's ROE is -1.05%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, UPH is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs OMCL Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, OMCL has a market cap of 1.32B. Regarding current trading prices, UPH is priced at $0.30, while OMCL trades at $28.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas OMCL's P/E ratio is 61.37. In terms of profitability, UPH's ROE is -1.05%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, UPH is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs TDOC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, TDOC has a market cap of 1.19B. Regarding current trading prices, UPH is priced at $0.30, while TDOC trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas TDOC's P/E ratio is -1.15. In terms of profitability, UPH's ROE is -1.05%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, UPH is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs TXG Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, TXG has a market cap of 1.02B. Regarding current trading prices, UPH is priced at $0.30, while TXG trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas TXG's P/E ratio is -6.28. In terms of profitability, UPH's ROE is -1.05%, compared to TXG's ROE of -0.22%. Regarding short-term risk, UPH is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs NUTX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, NUTX has a market cap of 890.23M. Regarding current trading prices, UPH is priced at $0.30, while NUTX trades at $159.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas NUTX's P/E ratio is 12.95. In terms of profitability, UPH's ROE is -1.05%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, UPH is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs EVH Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, EVH has a market cap of 846.45M. Regarding current trading prices, UPH is priced at $0.30, while EVH trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas EVH's P/E ratio is -5.91. In terms of profitability, UPH's ROE is -1.05%, compared to EVH's ROE of -0.11%. Regarding short-term risk, UPH is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs HSTM Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, HSTM has a market cap of 834.56M. Regarding current trading prices, UPH is priced at $0.30, while HSTM trades at $27.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas HSTM's P/E ratio is 43.40. In terms of profitability, UPH's ROE is -1.05%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, UPH is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SLP Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SLP has a market cap of 664.57M. Regarding current trading prices, UPH is priced at $0.30, while SLP trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SLP's P/E ratio is 91.79. In terms of profitability, UPH's ROE is -1.05%, compared to SLP's ROE of +0.04%. Regarding short-term risk, UPH is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs MPLN-WT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MPLN-WT has a market cap of 625.23M. Regarding current trading prices, UPH is priced at $0.30, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, UPH is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs ACCD Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ACCD has a market cap of 575.59M. Regarding current trading prices, UPH is priced at $0.30, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ACCD's P/E ratio is -3.08. In terms of profitability, UPH's ROE is -1.05%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, UPH is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CCLDP Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CCLDP has a market cap of 566.58M. Regarding current trading prices, UPH is priced at $0.30, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CCLDP's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, UPH is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SHCR Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SHCR has a market cap of 531.78M. Regarding current trading prices, UPH is priced at $0.30, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SHCR's P/E ratio is -3.76. In terms of profitability, UPH's ROE is -1.05%, compared to SHCR's ROE of -0.29%. Regarding short-term risk, UPH is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CTEV Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CTEV has a market cap of 437.54M. Regarding current trading prices, UPH is priced at $0.30, while CTEV trades at $26.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CTEV's P/E ratio is -0.37. In terms of profitability, UPH's ROE is -1.05%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, UPH is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SLGCW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SLGCW has a market cap of 396.23M. Regarding current trading prices, UPH is priced at $0.30, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, UPH's ROE is -1.05%, compared to SLGCW's ROE of -0.09%. Regarding short-term risk, UPH is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs SLGC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SLGC has a market cap of 396.23M. Regarding current trading prices, UPH is priced at $0.30, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SLGC's P/E ratio is -3.04. In terms of profitability, UPH's ROE is -1.05%, compared to SLGC's ROE of -0.09%. Regarding short-term risk, UPH is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs MPLN Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MPLN has a market cap of 374.98M. Regarding current trading prices, UPH is priced at $0.30, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MPLN's P/E ratio is -0.23. In terms of profitability, UPH's ROE is -1.05%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, UPH is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs TBRG Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, TBRG has a market cap of 356.51M. Regarding current trading prices, UPH is priced at $0.30, while TBRG trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas TBRG's P/E ratio is -19.45. In terms of profitability, UPH's ROE is -1.05%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, UPH is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SPOK Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SPOK has a market cap of 326.48M. Regarding current trading prices, UPH is priced at $0.30, while SPOK trades at $15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SPOK's P/E ratio is 20.61. In terms of profitability, UPH's ROE is -1.05%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, UPH is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs DH Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, DH has a market cap of 324.17M. Regarding current trading prices, UPH is priced at $0.30, while DH trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas DH's P/E ratio is -0.68. In terms of profitability, UPH's ROE is -1.05%, compared to DH's ROE of -1.07%. Regarding short-term risk, UPH is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs NRC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, NRC has a market cap of 309.65M. Regarding current trading prices, UPH is priced at $0.30, while NRC trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas NRC's P/E ratio is 13.32. In terms of profitability, UPH's ROE is -1.05%, compared to NRC's ROE of +0.71%. Regarding short-term risk, UPH is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs TRHC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, TRHC has a market cap of 284.03M. Regarding current trading prices, UPH is priced at $0.30, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas TRHC's P/E ratio is -4.27. In terms of profitability, UPH's ROE is -1.05%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, UPH is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs HCAT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, HCAT has a market cap of 254.04M. Regarding current trading prices, UPH is priced at $0.30, while HCAT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas HCAT's P/E ratio is -3.17. In terms of profitability, UPH's ROE is -1.05%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, UPH is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SMFR Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SMFR has a market cap of 246.37M. Regarding current trading prices, UPH is priced at $0.30, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SMFR's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, UPH is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs OPRX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, OPRX has a market cap of 215.47M. Regarding current trading prices, UPH is priced at $0.30, while OPRX trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas OPRX's P/E ratio is -13.87. In terms of profitability, UPH's ROE is -1.05%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, UPH is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SOPH Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SOPH has a market cap of 190.47M. Regarding current trading prices, UPH is priced at $0.30, while SOPH trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SOPH's P/E ratio is -2.85. In terms of profitability, UPH's ROE is -1.05%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, UPH is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs EUDA Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, EUDA has a market cap of 141.57M. Regarding current trading prices, UPH is priced at $0.30, while EUDA trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas EUDA's P/E ratio is -7.06. In terms of profitability, UPH's ROE is -1.05%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, UPH is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CPSI Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CPSI has a market cap of 133.71M. Regarding current trading prices, UPH is priced at $0.30, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CPSI's P/E ratio is -183.80. In terms of profitability, UPH's ROE is -1.05%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, UPH is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs AMWL Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, AMWL has a market cap of 118.26M. Regarding current trading prices, UPH is priced at $0.30, while AMWL trades at $7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas AMWL's P/E ratio is -0.74. In terms of profitability, UPH's ROE is -1.05%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, UPH is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs AUGX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, AUGX has a market cap of 115.91M. Regarding current trading prices, UPH is priced at $0.30, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas AUGX's P/E ratio is -4.99. In terms of profitability, UPH's ROE is -1.05%, compared to AUGX's ROE of -1.82%. Regarding short-term risk, UPH is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SY Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SY has a market cap of 110.74M. Regarding current trading prices, UPH is priced at $0.30, while SY trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SY's P/E ratio is -1.05. In terms of profitability, UPH's ROE is -1.05%, compared to SY's ROE of -0.26%. Regarding short-term risk, UPH is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CCLDO Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CCLDO has a market cap of 85.61M. Regarding current trading prices, UPH is priced at $0.30, while CCLDO trades at $19.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CCLDO's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, UPH is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CCLD Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CCLD has a market cap of 83.97M. Regarding current trading prices, UPH is priced at $0.30, while CCLD trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CCLD's P/E ratio is -9.02. In terms of profitability, UPH's ROE is -1.05%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, UPH is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs FORA Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, FORA has a market cap of 64.59M. Regarding current trading prices, UPH is priced at $0.30, while FORA trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas FORA's P/E ratio is -17.25. In terms of profitability, UPH's ROE is -1.05%, compared to FORA's ROE of -0.13%. Regarding short-term risk, UPH is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs BEATW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, BEATW has a market cap of 57.18M. Regarding current trading prices, UPH is priced at $0.30, while BEATW trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas BEATW's P/E ratio is -1.09. In terms of profitability, UPH's ROE is -1.05%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, UPH is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs BEAT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, BEAT has a market cap of 56.12M. Regarding current trading prices, UPH is priced at $0.30, while BEAT trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas BEAT's P/E ratio is -2.24. In terms of profitability, UPH's ROE is -1.05%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, UPH is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SNCE Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SNCE has a market cap of 34.66M. Regarding current trading prices, UPH is priced at $0.30, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SNCE's P/E ratio is -0.27. In terms of profitability, UPH's ROE is -1.05%, compared to SNCE's ROE of -0.59%. Regarding short-term risk, UPH is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs AKLI Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, AKLI has a market cap of 34.10M. Regarding current trading prices, UPH is priced at $0.30, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas AKLI's P/E ratio is -0.71. In terms of profitability, UPH's ROE is -1.05%, compared to AKLI's ROE of -0.74%. Regarding short-term risk, UPH is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SHLT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SHLT has a market cap of 33.60M. Regarding current trading prices, UPH is priced at $0.30, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SHLT's P/E ratio is -3.87. In terms of profitability, UPH's ROE is -1.05%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, UPH is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SHCRW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SHCRW has a market cap of 32.55M. Regarding current trading prices, UPH is priced at $0.30, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, UPH's ROE is -1.05%, compared to SHCRW's ROE of -0.29%. Regarding short-term risk, UPH is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs RNLX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, RNLX has a market cap of 22.55M. Regarding current trading prices, UPH is priced at $0.30, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas RNLX's P/E ratio is -0.33. In terms of profitability, UPH's ROE is -1.05%, compared to RNLX's ROE of +2.93%. Regarding short-term risk, UPH is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs LIFW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, LIFW has a market cap of 22.36M. Regarding current trading prices, UPH is priced at $0.30, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas LIFW's P/E ratio is -0.02. In terms of profitability, UPH's ROE is -1.05%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, UPH is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs MGRX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MGRX has a market cap of 18.76M. Regarding current trading prices, UPH is priced at $0.30, while MGRX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MGRX's P/E ratio is -0.37. In terms of profitability, UPH's ROE is -1.05%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, UPH is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs VSEEW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, VSEEW has a market cap of 18.26M. Regarding current trading prices, UPH is priced at $0.30, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas VSEEW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, UPH is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs BFRG Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, BFRG has a market cap of 17.42M. Regarding current trading prices, UPH is priced at $0.30, while BFRG trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas BFRG's P/E ratio is -2.31. In terms of profitability, UPH's ROE is -1.05%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, UPH is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs VSEE Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, VSEE has a market cap of 17.07M. Regarding current trading prices, UPH is priced at $0.30, while VSEE trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas VSEE's P/E ratio is -13.62. In terms of profitability, UPH's ROE is -1.05%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, UPH is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs BBLN Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, BBLN has a market cap of 14.10M. Regarding current trading prices, UPH is priced at $0.30, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas BBLN's P/E ratio is -0.04. In terms of profitability, UPH's ROE is -1.05%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, UPH is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs INOV Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, INOV has a market cap of 13.81M. Regarding current trading prices, UPH is priced at $0.30, while INOV trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas INOV's P/E ratio is 16.58. In terms of profitability, UPH's ROE is -1.05%, compared to INOV's ROE of +0.03%. Regarding short-term risk, UPH is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs ONMD Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ONMD has a market cap of 12.50M. Regarding current trading prices, UPH is priced at $0.30, while ONMD trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ONMD's P/E ratio is -1.20. In terms of profitability, UPH's ROE is -1.05%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, UPH is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs MSPR Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MSPR has a market cap of 12.20M. Regarding current trading prices, UPH is priced at $0.30, while MSPR trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MSPR's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, UPH is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs SCNX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SCNX has a market cap of 11.50M. Regarding current trading prices, UPH is priced at $0.30, while SCNX trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SCNX's P/E ratio is 1.33. In terms of profitability, UPH's ROE is -1.05%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, UPH is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs ETAO Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ETAO has a market cap of 9.78M. Regarding current trading prices, UPH is priced at $0.30, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ETAO's P/E ratio is -0.01. In terms of profitability, UPH's ROE is -1.05%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, UPH is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs STRM Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, STRM has a market cap of 9.40M. Regarding current trading prices, UPH is priced at $0.30, while STRM trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas STRM's P/E ratio is -0.86. In terms of profitability, UPH's ROE is -1.05%, compared to STRM's ROE of -0.68%. Regarding short-term risk, UPH is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs HLTH Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, HLTH has a market cap of 6.90M. Regarding current trading prices, UPH is priced at $0.30, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas HLTH's P/E ratio is -0.02. In terms of profitability, UPH's ROE is -1.05%, compared to HLTH's ROE of -1.04%. Regarding short-term risk, UPH is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs OTRK Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, OTRK has a market cap of 6.62M. Regarding current trading prices, UPH is priced at $0.30, while OTRK trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas OTRK's P/E ratio is -0.09. In terms of profitability, UPH's ROE is -1.05%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, UPH is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs ZCMD Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ZCMD has a market cap of 5.99M. Regarding current trading prices, UPH is priced at $0.30, while ZCMD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ZCMD's P/E ratio is -9.58. In terms of profitability, UPH's ROE is -1.05%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, UPH is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs EUDAW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, EUDAW has a market cap of 5.76M. Regarding current trading prices, UPH is priced at $0.30, while EUDAW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas EUDAW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, UPH is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs PEAR Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, PEAR has a market cap of 4.09M. Regarding current trading prices, UPH is priced at $0.30, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas PEAR's P/E ratio is -0.08. In terms of profitability, UPH's ROE is -1.05%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, UPH is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs PEARW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, PEARW has a market cap of 4.09M. Regarding current trading prices, UPH is priced at $0.30, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas PEARW's P/E ratio is -0.00. In terms of profitability, UPH's ROE is -1.05%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, UPH is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs ICCT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ICCT has a market cap of 3.86M. Regarding current trading prices, UPH is priced at $0.30, while ICCT trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ICCT's P/E ratio is -0.03. In terms of profitability, UPH's ROE is -1.05%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, UPH is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs ACON Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ACON has a market cap of 3.86M. Regarding current trading prices, UPH is priced at $0.30, while ACON trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ACON's P/E ratio is -0.58. In terms of profitability, UPH's ROE is -1.05%, compared to ACON's ROE of -1.27%. Regarding short-term risk, UPH is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs FOXO Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, FOXO has a market cap of 3.29M. Regarding current trading prices, UPH is priced at $0.30, while FOXO trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas FOXO's P/E ratio is -0.05. In terms of profitability, UPH's ROE is -1.05%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, UPH is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs HCTI Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, HCTI has a market cap of 2.37M. Regarding current trading prices, UPH is priced at $0.30, while HCTI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas HCTI's P/E ratio is -0.01. In terms of profitability, UPH's ROE is -1.05%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, UPH is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs WGSWW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, WGSWW has a market cap of 1.82M. Regarding current trading prices, UPH is priced at $0.30, while WGSWW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas WGSWW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, UPH is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs CMAX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CMAX has a market cap of 1.61M. Regarding current trading prices, UPH is priced at $0.30, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CMAX's P/E ratio is -0.00. In terms of profitability, UPH's ROE is -1.05%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, UPH is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs WORX Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, WORX has a market cap of 1.46M. Regarding current trading prices, UPH is priced at $0.30, while WORX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas WORX's P/E ratio is -0.45. In terms of profitability, UPH's ROE is -1.05%, compared to WORX's ROE of -0.32%. Regarding short-term risk, UPH is more volatile compared to WORX. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs LIFWZ Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, LIFWZ has a market cap of 1.25M. Regarding current trading prices, UPH is priced at $0.30, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, UPH is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs OTRKP Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, OTRKP has a market cap of 1.05M. Regarding current trading prices, UPH is priced at $0.30, while OTRKP trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, UPH's ROE is -1.05%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, UPH is more volatile compared to OTRKP. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs KERN Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, KERN has a market cap of 162320.00. Regarding current trading prices, UPH is priced at $0.30, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas KERN's P/E ratio is -0.01. In terms of profitability, UPH's ROE is -1.05%, compared to KERN's ROE of -2.22%. Regarding short-term risk, UPH is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs KERNW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, KERNW has a market cap of 162320.00. Regarding current trading prices, UPH is priced at $0.30, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas KERNW's P/E ratio is -0.00. In terms of profitability, UPH's ROE is -1.05%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, UPH is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs LIFWW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, LIFWW has a market cap of 60053.00. Regarding current trading prices, UPH is priced at $0.30, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas LIFWW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, UPH is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs MSPRZ Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MSPRZ has a market cap of 48272.00. Regarding current trading prices, UPH is priced at $0.30, while MSPRZ trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, UPH is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs CMAXW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CMAXW has a market cap of 36386.00. Regarding current trading prices, UPH is priced at $0.30, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CMAXW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, UPH is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs ACONW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, ACONW has a market cap of 17529.00. Regarding current trading prices, UPH is priced at $0.30, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas ACONW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, UPH is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs MSPRW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MSPRW has a market cap of 6219.00. Regarding current trading prices, UPH is priced at $0.30, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MSPRW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, UPH and MSPRW have similar daily volatility (18.18).
UPH vs UTRS Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, UTRS has a market cap of 888.00. Regarding current trading prices, UPH is priced at $0.30, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas UTRS's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, UPH is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CHNGU Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CHNGU has a market cap of N/A. Regarding current trading prices, UPH is priced at $0.30, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CHNGU's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, UPH is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CNVY Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CNVY has a market cap of N/A. Regarding current trading prices, UPH is priced at $0.30, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CNVY's P/E ratio is -71.50. In terms of profitability, UPH's ROE is -1.05%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, UPH is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs SMFRW Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, SMFRW has a market cap of N/A. Regarding current trading prices, UPH is priced at $0.30, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas SMFRW's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, UPH is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for UPH.
UPH vs MTBC Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, MTBC has a market cap of N/A. Regarding current trading prices, UPH is priced at $0.30, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas MTBC's P/E ratio is N/A. In terms of profitability, UPH's ROE is -1.05%, compared to MTBC's ROE of +0.21%. Regarding short-term risk, UPH is more volatile compared to MTBC. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.
UPH vs CSLT Comparison
UPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPH stands at 5.33M. In comparison, CSLT has a market cap of N/A. Regarding current trading prices, UPH is priced at $0.30, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPH currently has a P/E ratio of -0.07, whereas CSLT's P/E ratio is -37.27. In terms of profitability, UPH's ROE is -1.05%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, UPH is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for UPH.